Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. May 15, 2025; 17(5): 105027
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105027
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105027
Table 4 Comparison of adverse reaction rates in patients with metastatic colorectal cancer in the targeted and target-exempted groups, n (%)
| All grades | χ2 | P value | Grade 3-4 | |||
| TT | TT + ICI | TT | TT + ICI | |||
| Hypertension | 14 (20.6) | 5 (16.1) | 0.06 | 0.805 | 2 (2.9) | 0 (0.0) |
| Proteinuria | 9 (13.2) | 3 (9.7) | -1 | 0.748 | 0 (0.0) | 0 (0.0) |
| Rash | 5 (7.4) | 3 (9.7) | -1 | 0.703 | 0 (0.0) | 0 (0.0) |
| Abnormal myocardial enzymes | 3 (4.4) | 3 (9.7) | -1 | 0.374 | 0 (0.0) | 0 (0.0) |
| Liver function impairment | 13 (19.1) | 4 (12.9) | 0.22 | 0.636 | 0 (0.0) | 0 (0.0) |
| Occult blood positive | 4 (5.9) | 3 (9.7) | -1 | 0.674 | 0 (0.0) | 0 (0.0) |
| Hand-foot skin reaction | 8 (11.8) | 2 (6.5) | -1 | 0.499 | 0 (0.0) | 0 (0.0) |
| Dysphonia | 3 (4.4) | 5 (16.1) | - | 0.104 | 0 (0.0) | 0 (0.0) |
| Fatigue | 24 (35.3) | 10 (32.3) | 0.00 | 0.947 | 1 (1.5) | 0 (0.0) |
| Decreased appetite | 12 (17.6) | 3 (9.7) | -1 | 0.378 | 0 (0.0) | 0 (0.0) |
| Bilirubin level elevated | 9 (13.2) | 2 (6.5) | -1 | 0.494 | 0 (0.0) | 0 (0.0) |
| Hypothyroidism | 2 (2.9) | 0 (0.0) | -1 | 1.000 | 0 (0.0) | 0 (0.0) |
| Platelet count decreased | 5 (7.4) | 3 (9.7) | -1 | 0.703 | 1 (1.5) | 0 (0.0) |
| Diarrhea | 9 (13.2) | 3 (9.7) | -1 | 0.748 | 0 (0.0) | 0 (0.0) |
- Citation: Wang PJ, Wang J, Yao XM, Cheng WL, Sun L, Yan J, Yu YL, Li SY, Li DP, Jia JH. Evaluation of efficacy and safety of targeted therapy and immune checkpoint inhibitors in metastatic colorectal cancer. World J Gastrointest Oncol 2025; 17(5): 105027
- URL: https://www.wjgnet.com/1948-5204/full/v17/i5/105027.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.105027